Synaptogyrin 3: A Promising Drug Target and Biomarker for neurological disorders

Target Name: SYNGR3

NCBI ID: G9143

SYNGR3

Other Name(s): synaptogyrin 3 | SNG3_HUMAN | Synaptogyrin-3 | Synaptogyrin 3

Synaptogyrin 3: A Promising Drug Target and Biomarker for neurological disorders

Introduction

Synaptogyrin 3 (SYNGR3) is a protein that is expressed in various tissues of the brain, including the prefrontal cortex, cerebellum, and central nervous system (CNS). It is a member of the glycophospholipid (GP) family, which includes several other well -known proteins, such ascalbindin, transthyretin, and MAPT. These proteins are involved in various physiological processes in the brain, including neuronal signaling, synaptic structure, and neurotransmitter release.

SYNGR3 function and role in neurological disorders

SYNGR3 is involved in multiple signaling pathways that are important for brain development, function, and disease. One of the well-known functions of SYNGR3 is its role in the development and maintenance of synaptic plasticity, which is the ability of the nervous system to change and adapt over time.

SYNGR3 is involved in the regulation of neurotransmitter release from neurons, which is critical for the function of the nervous system. It does this by playing a role in the presynaptic terminal (PNT) of neurons, which is the site where neurotransmitters are released from the axon terminal of the neuron.

In addition to its role in neurotransmitter release, SYNGR3 is also involved in the regulation of synaptic strength, which is the ability of synapses to transmit signals between neurons. It does this by playing a role in the structure and composition of the synapse, as well as by regulating the activity of other proteins that are involved in synaptic strength.

SYNGR3 is also involved in the regulation of neuronal excitability, which is the ability of neurons to generate electrical signals. It does this by playing a role in the intracellular signaling pathways that are involved in neuronal excitability, including the regulation of ion channels and the production of reactive oxygen species (ROS).

Diseases associated with SYNGR3 dysfunction

SYNGR3 dysfunction has been implicated in the development and progression of several neurological disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These disorders are characterized by the progressive loss of brain cells and the formation of aggregates of damaged proteins, which can disrupt the function of the nervous system.

In Alzheimer's disease, SYNGR3 has been shown to be involved in the development and progression of neurodegeneration in the brain. Studies have shown that individuals with Alzheimer's disease have lower levels of SYNGR3 than those without the disease. Additionally, the levels of SYNGR3 have been shown to be correlated with the severity of neurodegeneration in individuals with Alzheimer's disease.

In Parkinson's disease, SYNGR3 has been implicated in the development and progression of motor neuron dysfunction. Studies have shown that individuals with Parkinson's disease have lower levels of SYNGR3 than those without the disease. Additionally, the levels of SYNGR3 have been shown to be correlated with the severity of motor neuron dysfunction in individuals with Parkinson's disease.

In Huntington's disease, SYNGR3 has been implicated in the development and progression of the disease. Studies have shown that individuals with Huntington's disease have lower levels of SYNGR3 than those without the disease. Additionally, the levels of SYNGR3 have been shown to be correlated with the severity of the disease in individuals with Huntington's disease.

Suggestions for drug targeting and biomarkers

Given the role of SYNGR3 in multiple signaling pathways that are important for brain development, function, and disease, drug targeting and biomarkers for SYNGR3 have great potential.

One approach to drug targeting

Protein Name: Synaptogyrin 3

Functions: May play a role in regulated exocytosis. May indirectly regulate the activity of the plasma membrane dopamine transporter SLC6A3 and thereby regulate dopamine transport back from the synaptic cleft into the presynaptic terminal

The "SYNGR3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SYNGR3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets